Immunic Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Immunic Stock Summary

Immunic competes with Generation Bio, Kronos Bio, Erasca, C4 Therapeutics, and Edgewise Therapeutics. Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people.

Immunic Key Financial Ratios

Immunic Key Balance Sheet Accounts

Immunic Key Income Statement Accounts

Immunic Key Cash Accounts

Immunic Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Immunic's current stock value. Our valuation model uses many indicators to compare Immunic value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunic competition to find correlations between indicators driving Immunic's intrinsic value. More Info.Immunic is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Immunic's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunic's earnings, one of the primary drivers of an investment's value.

Immunic Systematic Risk

Today, most investors in Immunic Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immunic's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Immunic growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Immunic help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Immunic. We use our internally-developed statistical techniques to arrive at the intrinsic value of Immunic based on widely used predictive technical indicators. In general, we focus on analyzing Immunic Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Immunic's daily price indicators and compare them against related drivers.

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.